Unknown

Dataset Information

0

Pyridoxine-responsive KCNQ2 epileptic encephalopathy: Additional cases and literature review.


ABSTRACT:

Background

Typical patients with KCNQ2 (OMIM# 602235) epileptic encephalopathy present early neonatal-onset intractable seizures with a burst suppression EEG pattern and severe developmental delay or regression, and those patients always fail first-line treatment with sodium channel blockers. Vitamin B6, either pyridoxine or pyridoxal 50-phosphate, has been demonstrated to improve seizure control in intractable epilepsy.

Methods

Here, we collected and summarized the clinical data for four independent cases diagnosed with pyridoxine-responsive epileptic encephalopathy, and their exome sequencing data. Moreover, we reviewed all published cases and summarized the clinical features, genetic variants, and treatment of pyridoxine-responsive KCNQ2 epileptic encephalopathy.

Results

All four cases showed refractory seizures during the neonatal period or infancy, accompanied by global development delay. Four pathogenetic variants of KCNQ2 were uncovered and confirmed by Sanger sequencing: KCNQ2 [NM_172107.4: c.2312C > T (p.Thr771Ile), c.873G > C (p.Arg291Ser), c.652 T > A (p.Trp218Arg) and c.913-915del (p. Phe305del)]. Sodium channel blockers and other anti-seizure medications failed to control their seizures. The frequency of seizures gradually decreased after treatment with high-dose pyridoxine. In case 1, case 2, and case 4, clinical seizures relapsed when pyridoxine was withdrawn, and seizures were controlled again when pyridoxine treatment was resumed.

Conclusion

Our study suggests that pyridoxine may be a promising adjunctive treatment option for patients with KCNQ2 epileptic encephalopathy.

SUBMITTER: Chen J 

PROVIDER: S-EPMC9544210 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pyridoxine-responsive KCNQ2 epileptic encephalopathy: Additional cases and literature review.

Chen Jun J   Tao Qiuji Q   Fan Lijuan L   Shen Yajun Y   Liu Jinfeng J   Luo Huan H   Yang Zuozhen Z   Liang Mengmeng M   Gan Jing J  

Molecular genetics & genomic medicine 20220730 10


<h4>Background</h4>Typical patients with KCNQ2 (OMIM# 602235) epileptic encephalopathy present early neonatal-onset intractable seizures with a burst suppression EEG pattern and severe developmental delay or regression, and those patients always fail first-line treatment with sodium channel blockers. Vitamin B6, either pyridoxine or pyridoxal 50-phosphate, has been demonstrated to improve seizure control in intractable epilepsy.<h4>Methods</h4>Here, we collected and summarized the clinical data  ...[more]

Similar Datasets

| S-EPMC7951099 | biostudies-literature
| S-EPMC4271583 | biostudies-literature
| S-EPMC7075958 | biostudies-literature
| S-EPMC10366601 | biostudies-literature
| S-EPMC9777507 | biostudies-literature
| PRJEB4676 | ENA
| S-EPMC10891437 | biostudies-literature
| S-EPMC11812603 | biostudies-literature
| S-EPMC10374643 | biostudies-literature